A Brief Primer On Interferons And SARS-CoV-2


As the coronavirus disease (COVID-19) pandemic continues to affect millions worldwide, PBL aims to continue to provide support to researchers around the world.

Below you can find a collection of peer-reviewed articles utilizing some of PBL’s products in SARS-CoV-2-related research.

You can also find an article detailing the relationship between IFN and SARS-CoV-2.

Featured Peer-Reviewed Publications

Cited Protein: Human IFN-Alpha Hybrid (Universal Type I IFN) (Cat. # 11200)

Cited ELISA: Human IFN-Beta ELISA, High Sensitivity (Cat. # 41415-1)

Cited ELISA: Mouse IFN-Beta ELISA (Cat. # 42400)

Cited Protein: Mouse IL-28B/IFN Lambda 3 (Cat. # 12820-1)

Cited ELISA: Human IFN-Alpha All Subtype ELISA (Cat. # 41115-1)

Article – A Brief Primer on Interferons and SARS-CoV-2

The coronavirus disease 2019 (COVID-19) pandemic has affected millions worldwide since its emergence over a year ago. Similar to other coronaviruses, the causative agent of COVID-19, SARS-CoV-2, is highly transmissible and causes a broad spectrum of disease including mild to severe respiratory symptoms. In addition to significant mortality in high-risk populations, COVID-19 appears to cause long-lasting morbidity in an estimated 10% of all cases, irrespective of age or underlying health factors (long-COVID or chronic COVID syndrome)1. In a remarkably short time, more has been published regarding this disease than any other disease in modern history; however, much remains unknown. A large part of this effort has been focused on how dysregulated immune responses, and type I interferon (IFN) in particular, contribute to disease progression. Underscoring the role of the innate immune system, a recent search for predisposing genetic risk factors for severe disease revealed that human inborn errors of type I IFNs may underlie more than 12.5% of severe COVID-19 cases in men and 2.6% in women2.


Read more about PBL here.

Subscribe to our newsletter

Get the latest news within your area of research to your inbox.
Subscribe →